Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses
Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is a proof of concept, randomized, double-blind, placebo-controlled, 2-arm, parallel
group study of Isoxsuprine in MS subjects experiencing a typical relapse.
Evidence from preclinical stroke models and experimental allergic encephalomyelitis suggest
that isoxsuprine hydrochloride may have neuroprotective activity and reduce disability in
animal models. Given its potential neuroprotective effects in CNS injury models, the
investigators propose to test it as a safe, tolerable add on treatment for acute relapses in
patients with relapsing forms of MS.